news
ELIQUIS® (apixaban) approved in Europe for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
20 November 2012 | By Bristol-Myers Squibb Company
The EC has approved ELIQUIS®...
List view / Grid view
Pfizer
news
Cystic Fibrosis Foundation Therapeutics announces $58 million CF drug discovery agreement with Pfizer
19 November 2012 | By Cystic Fibrosis Foundation
CFFT announced a major expansion of its research collaboration with Pfizer...
news
Pfizer reports top-line results of a Phase 3 study evaluating pregabalin controlled-release as treatment for patients with fibromyalgia
19 November 2012 | By Pfizer
Top-line results of a Phase 3 study...
news
Pfizer reports top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation as adjunctive treatment in adult patients with partial onset seizures
16 November 2012 | By Pfizer
Pfizer Inc., announced top-line results of a double-blind, placebo-controlled, Phase 3 study...
news
Amgen and Pfizer highlight data to be presented at American College of Rheumatology Meeting
12 November 2012 | By Amgen
Amgen and Pfizer announced that results from several Enbrel® (etanercept) studies...
news
Auxilium and Pfizer will conclude agreement on XIAPEX® EU collaboration
7 November 2012 | By Pfizer
Auxilium Pharmaceuticals, Inc., and Pfizer are amending their collaboration agreement...
news
U.S. Food and Drug Administration approves Pfizer’s XELJANZ® (tofacitinib citrate)
6 November 2012 | By Pfizer
The U.S. FDA has approved XELJANZ®...
news
Portola, Bristol-Myers Squibb and Pfizer sign clinical collaboration agreement
1 November 2012 | By Bristol-Myers Squibb Company
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer announced a clinical collaboration agreement...
article
Non-Destructive Material Identification In-Depth Focus 2012
In this Non-Destructive Material Identification In-Depth Focus: An implementation perspective on handheld Raman spectrometers for the verification of material identity; Portable Raman spectroscopy for pharmaceutical counterfeit detection; Ask the Experts...
news
Pfizer’s XALKORI® receives conditional marketing authorization from the European Commission
24 October 2012 | By Pfizer
Conditional marketing authorization for XALKORI® in the EU granted...
news
Pfizer to acquire NextWave Pharmaceuticals, Inc.
22 October 2012 | By Pfizer
Pfizer has announced its intention to acquire NextWave Pharmaceuticals...
news
Pfizer announces top-line results from phase 3 trial of INLYTA® (axitinib)
17 October 2012 | By Pfizer
In treatment-naïve patients with advanced renal cell carcinoma...
news
Pfizer announces top-line results from a Phase 3 long-term safety study of ALO-02
11 October 2012 | By Pfizer
“These top-line data provide evidence of the long-term safety of ALO-02..."
news
New report reveals programs that promote healthy ageing can help reduce rising health costs1
10 October 2012 | By Pfizer
In 2050, the number of people aged 60+ years worldwide will increase to nearly 2 billion...
news
Pfizer announces top-line results of Prevenar 13® Phase 3 Trial in adults 18 to 49 years of age
4 October 2012 | By Pfizer
Pfizer has announced top-line data...
